A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction.
about
Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationFluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4CPT: Pharmacometrics and Systems PharmacologyDrug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling.Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19Prediction of gestational age-dependent induction of in vivo hepatic CYP3A activity based on HepaRG cells and human hepatocytes.Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in PregnancyPhysiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.The Food and Drug Administration Office of Women's Health: Impact of Science on Regulatory Policy: An Update.Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models.A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women.The future of physiologically based pharmacokinetic modeling to predict drug exposure in pregnant women.The Promises of Quantitative Proteomics in Precision MedicineFixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability.The Prediction of the Relative Importance of CYP3A/P-glycoprotein to the Nonlinear Intestinal Absorption of Drugs by Advanced Compartmental Absorption and Transit Model.Translational systems pharmacology studies in pregnant women.Characterization of Maternal and Fetal CYP3A-Mediated Progesterone Metabolism.Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations.Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence.Inclusion of pregnant and breastfeeding women in research - efforts and initiatives.A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways.Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses.Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the model for passive placental permeability drugs.Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective
P2860
Q28088352-A820D8FF-0D7B-4B9B-B375-FC0BE5E37856Q28307990-349A8111-18E0-4E53-8066-A85F84D30945Q28709637-D4659AC4-19F5-4925-8A64-ADAE4AAE51A6Q34323195-EFFE739A-4CEC-4B41-8431-A75833C6BC04Q34571360-B34D6AF7-E4FA-4A44-A47B-24FF8D32B8A0Q35211432-B0AF67C5-BEA1-4007-83A8-AA5BD9C0E1DBQ35600241-AB7F03A4-FD9F-4DD1-B6F4-0C4AEBE5884DQ35797203-F18D4E6D-FDCD-4E56-A391-695191C04866Q36243626-A45B85EC-2900-4CF8-992B-763C07F47C13Q36683248-DE7FF9EE-CB70-4342-AC3F-58B93DE40637Q36706781-1DF1AC23-5414-44C3-A1BD-4ADEFBB8792FQ36717181-A75147DE-F3B3-422E-B0BA-6B4E3DB8A9BBQ36737498-A2FD51DB-3A98-472E-9728-912908883974Q37647264-5245FB51-09D4-463B-AFA8-1F88A4165C3AQ37712256-D8049B88-9727-46AE-9923-6CDB4B0D2D45Q39476375-631292F7-B96F-4F6F-8BBF-D32173C4AB69Q47312708-56810A4A-15A8-4BFE-AAD3-5ED3B01E3D8BQ47672239-E9184DB5-54A0-4605-A424-7B64C096A0A4Q47724161-482BADD9-8346-4D68-96E6-37F35E4B9AA2Q47813133-914E6572-09DA-4D40-A0AC-41DE85C43B81Q47963328-085C088A-4869-4F9D-9E22-EE9B5EAC90FDQ48072950-AC02BA83-0492-48A6-BD47-A8CAF805C86BQ50597914-F2DEF3A3-A28F-4119-814C-A9299EBA620DQ50974898-ED6EBDD2-803B-4E3C-A756-9C67151E4D5AQ58073610-DDFC8841-551A-4B3C-9BF5-C47B96B2F7B3
P2860
A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A PBPK Model to Predict Dispos ...... g the Site of CYP3A Induction.
@ast
A PBPK Model to Predict Dispos ...... g the Site of CYP3A Induction.
@en
type
label
A PBPK Model to Predict Dispos ...... g the Site of CYP3A Induction.
@ast
A PBPK Model to Predict Dispos ...... g the Site of CYP3A Induction.
@en
prefLabel
A PBPK Model to Predict Dispos ...... g the Site of CYP3A Induction.
@ast
A PBPK Model to Predict Dispos ...... g the Site of CYP3A Induction.
@en
P2093
P2860
P356
P1476
A PBPK Model to Predict Dispos ...... g the Site of CYP3A Induction.
@en
P2093
A Rostami-Hodjegan
J D Unadkat
S C Nallani
P2860
P356
10.1038/PSP.2012.2
P577
2012-09-26T00:00:00Z